Meeting
2014 ASCO Annual Meeting
Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum.
Authors
Morten Mau-Soerensen
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Morten Mau-Soerensen , Olfred Hansen , Bente Holm , Christa Haugaard Nyhus , Tine McCulloch , Henrik Anker Nielsen , Kim Wedervang , Carsten Rytter , Nina Jeppesen , Seppo Langer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00812266
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7519)
DOI
10.1200/jco.2014.32.15_suppl.7519
Abstract #
7519
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC).
First Author: Philip B. Komarnitsky
Poster
2022 ASCO Annual Meeting
Trends in treatment patterns associated with small cell lung cancer in a U.S. Medicare population.
First Author: Robert A. Ramirez
Poster
2017 ASCO Annual Meeting
A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian.
First Author: Luis G. Paz-Ares
Poster
2016 ASCO Annual Meeting
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.
First Author: Marcello Tiseo